Emerging Therapies & Innovations

Investing in the Future of Healthcare

Duopharma Biotech has invested in new and emerging healthcare therapies and technologies as a means to bring these innovations to its markets and to support further research and development in these areas – as an industry leader focused on offering innovative solutions to improve quality of life.

Alzheimer’s Disease

Duopharma Biotech has invested in AZTherapies Inc, a Boston-based biopharmaceutical company developing novel small molecules and biologic therapies that aim to fundamentally change neurodegenerative disease progression, extend normal cognition and function and improve quality of life in the ageing population.

This is expected to provide low-cost entry to access marketing and manufacturing rights of a novel product for Alzheimer’s Disease.

The burden of Alzheimer’s Disease has been outpacing the research, as the elderly population continues to grow worldwide. 

The number of people living with dementia – of which Alzheimer’s Disease is a major cause, is projected to increase exponentially, with the total health cost worldwide already estimated to be well over USD400 billion (RM1.7 trillion) a year. 

By 2030, it is estimated that there will be 64 million people living with dementia globally, and almost doubling to more than 115 million by 2050.  

Early diagnosis and management are important factors in mitigating the impact of Alzheimer’s Disease, and it is crucial to overcome the problem of under-diagnosis. Currently, only about 25% of people with Alzheimer’s Disease are diagnosed globally, including in Malaysia. 

In 2006, it was estimated that 63,000 people had Alzheimer’s Disease, with the current number double that and projected to reach 500,000 by 2050. 

According to the National Health and Morbidity Survey 2018, about one in 10 persons aged over 60 suffers from dementia, with prevalence higher among rural residents, women, people with no formal education, and people with lower income levels.

Digital Therapeutics

Duopharma Biotech has invested in Naluri Hidup, a local pioneer in digital therapeutics, which has developed the proprietary Naluri application, a digital health platform combining behavioural science, data science and digital design to offer a holistic health management programme for users.

The investment aligns with the Company’s belief in the smart application of digital technologies to enhance the effectiveness of healthcare and achieve the objective of a healthier life – optimising data science, predictive algorithms, device connectivity and disease monitoring to help everyone get healthier. 

Duopharma Biotech aims to integrate Naluri into the Specialty and Consumer Healthcare businesses and to offer premium health packages for customers.

The proprietary Naluri app-based platform offers human-led and artificial intelligence-augmented digital health coaching to help individuals address multiple chronic health conditions and to deliver quantifiable health outcomes. 

Naluri delivers structured multi-disciplinary support to those affected by chronic conditions such as diabetes, hypertension, heart disease, renal disease and cancer, and mental health conditions such as anxiety and depression. 

A key feature is the tailored and personalised professional coaching offered by qualified psychologists, dietitians, medical advisors, pharmacists, fitness coaches and even career coaches and financial planners, through the Naluri app. 

The coaching is supplemented by digital features including an Artificial Intelligence-powered food journal, a thought journal, a health curriculum of daily lessons, and a planner that includes reminders and tracking for medication adherence.

Stem Cell Therapies

Duopharma Biotech has invested in Korean stem cell firm SCM Lifescience, in line with the Company’s strategy to diversify into biotherapeutics and high-value niche products that can be applied in Malaysia and other markets. 

This offers the opportunity for early-stage entry at a reasonable cost.

The investment also offers access to SCM Lifescience’s portfolio, including Colmmune, a United States-based entity with an immuno-oncology global cell therapy facility.